Home » Stocks » DermTech

DermTech, Inc. (DMTK)

Stock Price: $11.60 USD 0.00 (0.00%)
Updated Jul 15, 2020 4:00 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 172.92M
Revenue (ttm) 4.33M
Net Income (ttm) -17.98M
Shares Out 18.11M
EPS (ttm) -3.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 15, 2020
Last Price $11.60
Previous Close $11.60
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 11.52 - 12.08
Day's Volume 0
52-Week Range 4.52 - 21.70

More Stats

Market Cap 172.92M
Enterprise Value 105.00M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 18.11M
Float 3.73M
EPS (basic) -1.44
EPS (diluted) -3.34
FCF / Share -1.95
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 349,096
Short Ratio 1.90
Short % of Float 3.06%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 39.98
PB Ratio 3.37
Revenue 4.33M
Operating Income -19.21M
Net Income -17.98M
Free Cash Flow -25.51M
Net Cash 67.92M
Net Cash / Share 4.56
Gross Margin 1.39%
Operating Margin -444.08%
Profit Margin -484.50%
FCF Margin -589.72%
ROA -36.16%
ROE -76.46%
ROIC -2,069.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$24.00*
Low
24.0
Current: 11.60
High
24.0
Target: 24.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182016
Revenue3.362.44-
Revenue Growth37.76%--
Gross Profit0.06-0.19-
Operating Income-17.61-8.56-
Net Income-19.69-10.00-
Shares Outstanding7.014.413.75
Earnings Per Share-2.81-2.27-
Operating Cash Flow-17.79-7.61-
Capital Expenditures-0.21-0.01-
Free Cash Flow-18.00-7.62-
Cash & Equivalents15.374.750.03
Total Debt-5.540.17
Net Cash / Debt15.37-0.78-0.14
Assets18.215.660.19
Liabilities5.7211.020.17
Book Value12.49-5.360.02
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name DermTech, Inc.
Country United States
Employees 60
CEO John D. Dobak

Stock Information

Ticker Symbol DMTK
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: DMTK

Description

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.